| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.06 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.06 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.06 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.06 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.06 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.06 |